



Industry-leading capabilities for heart failure research

Clinically Relevant Models
GemPharmatech's heart failure models closely mimic human disease progression, enabling accurate prediction of drug efficacy and safety profiles.
01

Comprehensive Assessment
Multi-parameter evaluation including echocardiography, hemodynamics, biomarkers,and histopathological analysis.
02

Customizable Study Design
Flexible protocols for acute and chronic heart failure studies, with options for surgical and pharmacological induction.
03
*Model has been used in IND-enabling studies
Explore our validated heart failure studies demonstrating the efficacy of various therapeutic interventions.

Panel A. ECG waveforms recorded within 5 minutes post-LAD, showing ST-segment elevation, indicating transmural ischemia due to complete occlusion of the left anterior coronary artery.
Panel B. Body weight changes over 4 weeks post-operation. LAD group exhibited a decrease in body weight compared to the Sham group during the first two weeks, followed by a gradual recovery.
Panel C. Survival curve over 4 weeks post-operation. Mortality in the LAD group occurred primarily during the first week, typically resulting from cardiac rupture and intrathoracic hemorrhage due to tear from shear stress during ventricular wall remodeling.
(A) Parasternal B-/M-mode images. (B) Echo data: Structural (IVSd/s, LVPWd/s), dimensional (LVIDd/s, LVEDV/ESV), and functional (EF, FS, SV, CO) parameters. The LAD group shows anterior wall thinning, LV dilation, and systolic dysfunction.

(A) Parasternal B-/M-mode images. (B) Echo data: Structural (IVSd/s, LVPWd/s), dimensional (LVIDd/s, LVEDV/ESV), and functional (EF, FS, SV, CO) parameters. The LAD group shows anterior wall thinning, LV dilation, and systolic dysfunction.

(A) Parasternal B-/M-mode images. (B) Echo data shows ventricular dilation, systolic dysfunction (reduced EF/FS), and arrhythmias. Parameters: wall thickness (IVSd/s, LVPWd/s), dimensions (LVIDd/s, LVEDV/ESV), and function (SV, CO).

(A) Gross morphology shows ventricular wall thinning and LV dilation. Heart weight/body weight (HW/BW) and HW/tibia length (HW/TL) ratios are elevated. (B) TTC staining: white indicates infarct region. (C) Masson's trichrome blue indicates fibrotic scars.

Mice received Entresto (Sac/Val) for 2 weeks post-modeling. Treatment slowed HF progression, primarily by reducing LV dilation (LVIDd/s, LVEDV, LVESV) and improving systolic function (EF, FS).

Entresto (Sac/Val) treatment demonstrated a cardioprotective effect, significantly reducing the infarct area. Quantification was performed using the midline method on multi-sectional Masson's trichrome-stained images (shown, apical to base), which demarcate fibrotic scars (blue).

Sham vs. MIRI groups at baseline (0h) and 24h post-op. MIRI shows significantly impaired systolic function (↓EF, FS, SV, CO), ventricular dilation (↑LVID;s/d, LVEDV, LVESV), and altered wall thickness at 24h (*p<0.05, **p<0.01).

Echo panel comparing Sham (●) and MIRI (◆) groups at baseline and 7 days post-op. MIRI shows significant systolic dysfunction (↓EF, FS, CO), ventricular dilation (↑LVEDV, LVESV, LVID;d), and altered wall thickness (IVS;d, LVPW;d) vs. Sham at 7dpa (ns, *, ,*). Data: mean±SEM.

Transverse heart sections (base to apex) from Sham and MIRI (14 days post-op) mice. Sham myocardium is uniformly brick-red (viable). MIRI hearts show extensive pale, unstained areas across sections, indicating transmural infarction


After 28G TAC surgery: 2-3 weeks shows compensatory ventricular hypertrophy (↑IVSd/s, LVPWd/s, LV dMass). By 4 weeks, ventricular dilation (↑LVIDd/s, LVEDV/ESV) and systolic dysfunction (↓EF, SV) develop, worsening over time.

(A) HW/BW and HW/TL ratios are significantly increased. (B) Coronal sections show enlarged hearts, thickened walls, dilated chambers, and marked fibrosis (replacement, perivascular, interstitial).

After 6-week Entresto (Sac/Val) treatment starting 4 weeks post-TAC (28G), phenotypes of ventricular dilation (↓LVESV) and systolic dysfunction (↑EF) were reversed, with a slight reduction in wall hypertrophy (trend in IVSd/s, LV dMass).

(A) Representative ECG waveforms and (B) statistical analysis from mice treated with ISO (30/50 mpk, osmotic pump). Increasing ISO concentration significantly prolonged the QT interval and elevated the ST segment and T wave.

Echocardiography shows that increasing ISO concentration elevates LV mass (indicating hypertrophy/edema) while significantly decreasing EF% and FS%, demonstrating impaired systolic function and pump failure.

Masson staining reveals 30 mpk ISO causes compensatory ventricular wall thickening. The 50 mpk dose leads to extensive cardiomyocyte death, resulting in wall thinning, ventricular cavity enlargement, and increased fibrosis.

Browse our comprehensive catalog of over 30,000 mouse models covering various gene families, signaling pathways, and disease models. Use advanced filters to find the perfect model for your research.
Discover related models and services to accelerate your research

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
